Swedish Biomimetics 3000® ’s plan is to operate as a Contract Development and Manufacturing Organisation (“CDMO”), providing peptide active pharmaceutical ingredients to the pharmaceutical industry in 2018.
In order to achieve this, the company is focused on commercialising an innovative, biomimetically inspired, pharmaceutical manufacturing technology, which enables the continuous production of various high value therapeutic oligomers (peptides and oligonucleotides). Peptides are of particular interest in the pharmaceutical industry for targeting disease given their high target specificity, high potency and their biodegradation to amino acids in the body. To date, two major barriers have impeded their adoption: high costs of production and route of administration. Significant improvements in the latter has reignited interest in peptides, however the challenge of high cost of production remains unanswered.
Swedish Biomimetics 3000® ’s technology – called Microlot (µLOT® ) is the first major disruption in therapeutic peptide manufacturing in the past 50 years. To date, therapeutic peptides have been manufactured in batch, which aside from reported high costs for pharmaceutical companies and health services/end-users, may also result in promising drugs being abandoned and approved drugs not reaching middle or low income markets. Batch production can also introduce risk of variable quality, long development times and supply volatility. µLOT® continuous production will address all of these problems.